Measuring movement behaviors in Bahraini adults with type 2 diabetes

Movement Behaviours Among Bahraini Type 2 Diabetic Adults: a Cross-sectional Study

Observational Royal College of Surgeons in Ireland - Medical University of Bahrain · NCT06069258

This study looks at how much Bahraini adults with type 2 diabetes move and sit during the day to see how these habits relate to their health and daily life.

Quick facts

Study typeObservational
Enrollment340 (estimated)
Ages20 Years to 75 Years
SexAll
SponsorRoyal College of Surgeons in Ireland - Medical University of Bahrain Academic / other
Locations4 sites (Building 10, Road 43, Manama and 3 other locations)
Trial IDNCT06069258 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the physical activity and sedentary behaviors of Bahraini patients with type 2 diabetes using accelerometer devices over a week. It will explore the relationships between these movement behaviors and various factors, including clinical parameters, psychological aspects, and environmental influences. The study also seeks to evaluate the feasibility and acceptability of using physical activity assessment tools in routine clinical practice. By understanding these behaviors, the research aims to inform future interventions to improve physical activity among this population.

Who should consider this trial

Good fit: Ideal candidates for this study are Bahraini adults aged 20-75 years with controlled type 2 diabetes and stable blood pressure and lipid levels.

Not a fit: Patients with uncontrolled diabetes, type 1 diabetes, or those who are non-ambulant may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved physical activity interventions for patients with type 2 diabetes, enhancing their overall health and management of the condition.

How similar studies have performed: While this approach is not widely tested in Bahrain, similar studies in other regions have shown success in understanding movement behaviors among diabetic populations.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Sex: Men and women are eligible.
* Age: Individuals aged 20-75 years old are eligible.
* Ethnicity: Bahraini adults of all ethnic groups are eligible for the study.
* Type 2 diabetes and glycaemic control: Individuals with controlled type 2 diabetes (i.e. HbA1c \<9 on medication) based on the medical record of each patient's last visit to the health centre for routine follow-up will be eligible if within the last four months. Otherwise, these measurements will be ordered at the first visit to confirm eligibility.
* Blood pressure: Individuals whose blood pressure is under moderate control will be eligible - specifically, treated or untreated resting systolic/diastolic pressure \< 160/100 mmHg.
* Lipid control: Individuals with fasting triglyceride concentration \< 600 mg are eligible.

Exclusion Criteria:

* HbA1c \>9%
* Type 1 diabetes
* Taking insulin
* Pregnancy
* Non-ambulant or severely incapacitated with any medical condition(s) reducing ability to stand or mobilize.
* Currently participating in a study to reduce sedentary behaviour or increase physical activity
* Language. Inability to read and understand Arabic or English language.
* Inability to give informed consent.

Where this trial is running

Building 10, Road 43, Manama and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Diabetes Mellitus, Type 2Physical activityBehaviourmHealth
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.